Excited to announce a new paper in ‪@aacrjournals.bsky.social‬ with Junwei Shi and Tony Daniyan. We perform screens of GAPs and GEFs in AML and discover a hematopoietic-specific GAP (ARHGAP45) required in a variety of hematologic malignancies: aacrjournals.org/cancerdiscov...

📢New Article published at Nature Cancer! ✒️By Christopher Klebanoff and colleagues 'CAR-engineered lymphocyte persistence is governed by a FAS ligand–FAS autoregulatory circuit' 🔗 www.nature.com/articles/s43...

MSK’s @klebanofflab.bsky.social and team found that FAS ligand, which hampers #CAR-T and #CAR-NK therapies, is actually produced by immune cells themselves.

Complete tumor eradication with cell therapies depends on persistence of donor CAR-cells in the patient @klebanofflab.bsky.social show that deletion of Fas on donor CAR-T/CAR-NK improves persistence in FasL-dependent (host NK & T) manner @natcancer.nature.com www.nature.com/articles/s43...

🚨Today, in #NatureCancer, we show that #CAR-T cells and #CAR-NK cells contain the seeds of their own self-destruction. Disruption of a FAS-L/FAS enhances CAR potency against liquid and solid cancers. rdcu.be/exjEy. @mskcancercenter.bsky.social @parkerici.bsky.social

MSK physician-scientist Dr. Christopher Klebanoff talked about all things #neoantigens for the Novel Classes of Human Cancer Rejection Antigens session this morning at #AACR25.

This is part of a long-standing collaboration with Rob Bradley’s lab ‪@fredhutch.bsky.social‬ and with amazing TCR discovery expertise from Chris Klebanoff’s lab @klebanofflab.bsky.social @mskcancercenter.bsky.social‬‬. Also incredible help from Jeff Molldrem @mdanderson.bsky.social‬‬‬‬‬